Rituximab With or Without Avacopan in ANCA-Associated Vasculitis With Severe Renal Involvement. (PubMed, Kidney Int Rep) - Sep 20, 2026 - "Avacopan significantly reduced cumulative prednisone exposure at 12 months (1.8 vs 4.3 g; P < 0.001) and shortened time to prednisone discontinuation (3.3 vs 7.3 months; log-rank P < 0.001). One patient (3.3%) discontinued avacopan because of drug-induced liver injury, with transaminase normalization after discontinuation. In our cohort of patients with AAV and severe renal involvement treated with rituximab-based induction, avacopan did not improve renal remission rates or longitudinal eGFR trajectory in comparison to glucocorticoids but achieved significant and faster glucocorticoid reduction with an acceptable safety profile."
Journal • ANCA Vasculitis • Glomerulonephritis • Hepatology • Liver Failure • Nephrology • Vasculitis
|
|
Anila Cara; Charat Thongprayoon; Cristián Juanet; Cristina García Majado; Fernando C Fervenza; Gian Marco Berti; Isabel Hassi; Jose A Meade-Aguilar; Jose Arriola-Montenegro; Ladan Zand; Maria J Vargas-Brochero; Samuel D Falde; Trisha Laxamana; Ulrich Specks
|